肝动脉栓塞治疗肝癌最新进展评述  

Advances in transarterial treatment of hepatocellular carcinoma

作　　者：贺庆[1] 官泳松[1] 杨宁宁[1] 熊飞[1] 李肖[2] 张靖宇[1] 谢勇久 

机构地区：[1]四川大学华西医院肿瘤一科,四川成都610041 [2]中国医学科学院肿瘤医院介入治疗科,北京100021

出　　处：《西部医学》2017年第9期1185-1193,共9页Medical Journal of West China

基　　金：国家自然科学基金面上项目(81171444)

摘　　要：肝癌是最常见的恶性肿瘤之一,全球每年有数十万计患者死于肝癌。经导管肝动脉化学栓塞(Transcatheter arterial chemoembolization,TACE)是一种临床广泛使用的治疗肝癌的方法。但是,如何通过TACE更好地使肝癌患者获益,仍然存在很多的挑战。本文回顾TACE治疗肝癌的发展过程,并重点就TACE栓塞剂以及TACE联合其他抗肿瘤方式治疗肝癌的最新进展做一评述。Hepatocellular carcinoma is a lethal disease that kills several homchad thousands of thousands of people every year across the globe. Transcatheter arterial chemoembolization（TACE） is a widely used approach in clinical practice to treat hepatocellular carcinoma（HCC）. However, we are now facing many challenges in the field of improving the survival outcomes of TACE for the treatment of HCC. This paper reviews recent advances in TACE treatment of HCC with the highlights of newly developed embolization agents and combiantion use of TACE and other treatment methods to get improved outcome of patients with HCC.

关 键 词：肝细胞癌 动脉化学栓塞 栓塞剂 联合治疗 

分 类 号：R735.7[医药卫生—肿瘤]